EXPRESS SCRIPTS, INC. for EXPRESS SCRIPTS, INC.

Defense DEF

Pharmacy issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act of 2012.

Contacted: U.S. Trade Representative (USTR); Congressional Budget Office (CBO); Labor, Dept of (DOL); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Defense, Dept of (DOD); Food & Drug Administration (FDA); Internal Revenue Service (IRS); Government Accountability Office (GAO); Federal Trade Commission (FTC); SENATE; HOUSE OF REPRESENTATIVES; White House Office; Health Resources & Services Administration (HRSA)

Trade (domestic/foreign) TRD

Trans Pacific Partnership trade agreements impact on biosimilar drug market exclusivity length.

Contacted: Federal Trade Commission (FTC); Defense, Dept of (DOD); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); Labor, Dept of (DOL); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; White House Office; Internal Revenue Service (IRS); SENATE; Government Accountability Office (GAO); Congressional Budget Office (CBO)

Labor Issues/Antitrust/Workplace LBR

Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surring proposed corporate merger.

Contacted: Congressional Budget Office (CBO); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Government Accountability Office (GAO); Federal Trade Commission (FTC); Executive Office of the President (EOP); Internal Revenue Service (IRS); Centers For Medicare and Medicaid Services (CMS); Defense, Dept of (DOD); SENATE; White House Office; Labor, Dept of (DOL); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Bills named: H.R. 1839 (112th), H.R. 1946 (112th), H.R. 1409 (112th)

Pharmacy PHA

Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).

Contacted: White House Office; Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES; Internal Revenue Service (IRS); Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); SENATE; Government Accountability Office (GAO); Labor, Dept of (DOL); Food & Drug Administration (FDA); Defense, Dept of (DOD)

Bills named: H.R. 1971 (112th), H.R. 979 (112th), S. 27 (112th)

Taxation/Internal Revenue Code TAX

HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors.

Contacted: Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Health Resources & Services Administration (HRSA); SENATE; Food & Drug Administration (FDA); Congressional Budget Office (CBO); Internal Revenue Service (IRS); Labor, Dept of (DOL); White House Office; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD); Health & Human Services, Dept of (HHS); Federal Trade Commission (FTC); Government Accountability Office (GAO)

Bills named: H.R. 4 (112th)

Health Issues HCR

Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)

Contacted: Food & Drug Administration (FDA); White House Office; Congressional Budget Office (CBO); Health Resources & Services Administration (HRSA); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); SENATE; Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Federal Trade Commission (FTC); Defense, Dept of (DOD); Labor, Dept of (DOL); Internal Revenue Service (IRS); Government Accountability Office (GAO); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Policy considerations of the Jt. Comm on Deficit Reduct

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Internal Revenue Service (IRS); Health Resources & Services Administration (HRSA); Congressional Budget Office (CBO); Executive Office of the President (EOP); Government Accountability Office (GAO); Labor, Dept of (DOL); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; White House Office; Federal Trade Commission (FTC); U.S. Trade Representative (USTR); SENATE; Defense, Dept of (DOD)

Bills named: H.R. 891 (112th), H.R. 905 (112th), H.R. 2190 (112th), H.R. 2248 (112th)